In cell models of early ETS‐driven PCa, we observed that coinhibition of EGFR and STAT3 pathways synergistically impaired cell growth in either ETV1‐ or ERG‐overexpressing cells, suggesting potential utility of the combination of TTI‐101 and Erlotinib for the treatment of both ETS‐positive PCa subtypes. Here, STAT3 is linked to posterior cortical atrophy.